Blood levels of two markers may help predict treatment response and outcomes in pulmonary arterial hypertension patients, per ...

Merck’s new pulmonary arterial hypertension (PAH) medication has posted another batch of promising clinical trial data, ...

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR).

A recent systematic review assessed the psychometric properties of various instruments for measuring QOL in patients with ...

Rising blood levels of an inflammatory marker, neutrophil-to-lymphocyte ratio, linked to poorer outcomes with chronic kidney ...

Tiprelestat was safe and well tolerated, with initial signs of clinical efficacyKiel, Germany, December 9, 2024 – tiakis Biotech AG, a ...

The Mini Nutritional Assessment was viable for assessing nutritional status and predicting mortality outcomes in patients ...

Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline ...

Pulmonary hypertension (PH), a life-threatening condition, is commonly seen in patients with interstitial lung disease (ILD), ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...

Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD) ...